SCHEMBL5545108

SCHEMBL5545108

[CH2]CCc1ccc(Oc2ccccc2C(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 1/20 0.51
LPAR5 Q9H1C0 1/20 0.51
LTA4H P09960 2/20 0.49
PTGS2 P35354 1/20 0.49
MAOB P27338 2/20 0.43
NR3C1 P04150 1/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
FFAR1 O14842 1/20 0.40
FDFT1 P37268 1/20 0.39
GAA P10253 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.38
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
AR P10275 5/20 0.38
PPARG P37231 1/20 0.38
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11521654 0.83 LTA4H (0.58) LPAR1LPAR5LTA4HPTGS2NR3C1
SCHEMBL12806556 0.81 LTA4H (0.51) LPAR1LPAR5LTA4HPTGS2MAOB
SCHEMBL923193 0.81 MAOB (0.57) LPAR1LPAR5LTA4HPTGS2MAOB
SCHEMBL5536466 0.78 LTA4H (0.51) LPAR1LPAR5LTA4HPTGS2NR3C1
SCHEMBL1676646 0.77 LTA4H (0.53) LPAR1LPAR5LTA4HPTGS2MAOB
SCHEMBL14677727 0.76 LTA4H (0.52) LPAR1LPAR5LTA4HPTGS2FFAR1
SCHEMBL476252 0.75 NCOA1 (0.51) LPAR1LPAR5LTA4HPTGS2MAOB
SCHEMBL3967756 0.75 LTA4H (0.51) LPAR1LPAR5LTA4HPTGS2NR3C1
SCHEMBL4308678 0.75 LTA4H (0.51) LPAR1LPAR5LTA4HPTGS2NR3C1
SCHEMBL5544769 0.75 TAAR1 (0.50) LTA4HMAOBFFAR1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LPAR1 2085/4885LPAR5 3648/4885LTA4H 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.